On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.
His survey at Stanford University’s Cantor Arts Center considers time’s supernatural and collective dimensions ...
Do you want your baby to have a vintage name that is not quite as popular as Henry, Liam, Emma or Charlotte? Step back in time with us. Maurice, Sylvia, Winifred and Eugene are quietly coming back, ...
Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...
2d
ViroGates A/S: ViroGates submits its De Novo application to the U.S. FDA for suPARnostic TurbiLatex
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results